Sarepta Therapeutics (NASDAQ:SRPT) reported three-year top-line results from its EMBARK Phase 3 pivotal trial evaluating ...
After a spate of patient deaths in 2025 linked to the company’s Duchenne gene therapy, Sarepta shared new data showing benefits of the therapy three years after dosing.
Zacks Investment Research on MSN
Keros Therapeutics vs. Dyne: Which DMD biotech has more upside?
Keros Therapeutics KROS is a clinical-stage biopharmaceutical company developing innovative therapies for patients with ...
Zacks Investment Research on MSN
SRPT stock up 8% on positive long-term data from Elevidys study in DMD
Sarepta Therapeutics SRPT announced positive three-year top-line data from Part 1 of the phase III EMBARK study, evaluating ...
Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.
Panelists discuss how the pooled 3-year data for delandistrogene moxeparvovec show sustained motor function stabilization and less deterioration compared with natural history, providing confidence in ...
By Mariam Sunny Jan 26 (Reuters) - Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy slowed disease ...
AMSTERDAM, Oct 13 (Reuters) - Dutch biotech company Amsterdam Molecular Therapeutics said its gene therapy treatment for Duchenne muscular dystrophy had been granted orphan drug designation by the ...
The US Food and Drug Administration (FDA) has approved the antisense oligonucleotide casimersen (Amondys 45, Sarepta Therapeutics) injection for the treatment of patients with Duchenne muscular ...
Panelists discuss how exciting ongoing research efforts are expanding similar gene therapy technologies to other muscular dystrophies like FSHD and myotonic dystrophy, using strategies to knock down ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results